Raras
Buscar doenças, sintomas, genes...
Hipoplasia das células de Leydig
ORPHA:755CID-10 · Q56.1CID-11 · LD2A.3DOENÇA RARA

Uma condição em homens que afeta o desenvolvimento sexual. É caracterizada pelo subdesenvolvimento das células de Leydig, que são células nos testículos que produzem hormônios sexuais masculinos (andrógenos) e são importantes para o desenvolvimento sexual masculino. Pessoas com LCH têm uma composição genética masculina típica (46, XY), mas devido aos níveis reduzidos de andrógenos, podem apresentar diversas diferenças nos órgãos genitais (órgãos reprodutores). Pessoas com LCH podem ter um pênis pequeno (micropênis), a abertura da uretra pode estar localizada na parte de baixo do pênis (hipospadia), ou a bolsa escrotal pode ser dividida em duas metades (escroto bífido). Devido a essas diferenças no desenvolvimento, os órgãos genitais externos podem não parecer claramente masculinos ou femininos (genitália ambígua). Algumas pessoas com LCH podem ter genitália externa feminina e testículos pequenos que não desceram e estão localizados na pelve, abdômen ou virilha. Isso pode ser chamado de tipo 1, enquanto casos menos graves podem ser chamados de tipo 2. A LCH é herdada de forma autossômica recessiva e é causada por mutações no gene LHCGR. Embora não haja um tratamento ou cura específica para a LCH, pode haver maneiras de controlar os sintomas. Frequentemente, é necessária uma equipe de médicos ou especialistas para determinar as opções de tratamento para cada pessoa.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma condição em homens que afeta o desenvolvimento sexual. É caracterizada pelo subdesenvolvimento das células de Leydig, que são células nos testículos que produzem hormônios sexuais masculinos (andrógenos) e são importantes para o desenvolvimento sexual masculino. Pessoas com LCH têm uma composição genética masculina típica (46, XY), mas devido aos níveis reduzidos de andrógenos, podem apresentar diversas diferenças nos órgãos genitais (órgãos reprodutores). Pessoas com LCH podem ter um pênis pequeno (micropênis), a abertura da uretra pode estar localizada na parte de baixo do pênis (hipospadia), ou a bolsa escrotal pode ser dividida em duas metades (escroto bífido). Devido a essas diferenças no desenvolvimento, os órgãos genitais externos podem não parecer claramente masculinos ou femininos (genitália ambígua). Algumas pessoas com LCH podem ter genitália externa feminina e testículos pequenos que não desceram e estão localizados na pelve, abdômen ou virilha. Isso pode ser chamado de tipo 1, enquanto casos menos graves podem ser chamados de tipo 2. A LCH é herdada de forma autossômica recessiva e é causada por mutações no gene LHCGR. Embora não haja um tratamento ou cura específica para a LCH, pode haver maneiras de controlar os sintomas. Frequentemente, é necessária uma equipe de médicos ou especialistas para determinar as opções de tratamento para cada pessoa.

Publicações científicas
94 artigos
Último publicado: 2025

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
70
pacientes catalogados
Início
Neonatal
🏥
SUS: Cobertura mínimaScore: 15%
CID-10: Q56.1
🇧🇷Dados SUS / DATASUS
PROCEDIMENTOS SIGTAP (5)
0202010503
Cariótipo — bandas G, Q ou Rgenetic_test
0202010600
Pesquisa de microdeleções/microduplicações por FISHlab_test
0202010694
Sequenciamento completo do exoma (WES)rehabilitation
0202010260
Dosagem de alfa-fetoproteína
0301070040
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
9 sintomas
🫘
Rins
2 sintomas
🧬
Pele e cabelo
2 sintomas
🦴
Ossos e articulações
1 sintomas

+ 25 sintomas em outras categorias

Características mais comuns

90%prev.
Micropênis
Muito frequente (99-80%)
90%prev.
Criptorquidia
Muito frequente (99-80%)
90%prev.
Hipogonadismo hipergonadotrófico
Muito frequente (99-80%)
90%prev.
Aplasia mamária
Muito frequente (99-80%)
90%prev.
Hipospadia
Muito frequente (99-80%)
90%prev.
Genitália ambígua
Muito frequente (99-80%)
39sintomas
Muito frequente (20)
Ocasional (3)
Sem dados (16)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 39 características clínicas mais associadas, ordenadas por frequência.

MicropênisMicropenis
Muito frequente (99-80%)90%
CriptorquidiaCryptorchidism
Muito frequente (99-80%)90%
Hipogonadismo hipergonadotróficoHypergonadotropic hypogonadism
Muito frequente (99-80%)90%
Aplasia mamáriaBreast aplasia
Muito frequente (99-80%)90%
HipospadiaHypospadias
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico94PubMed
Últimos 10 anos30publicações
Pico20205 papers
Linha do tempo
2025Hoje · 2026📈 2020Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

2 genes identificados com associação a esta condição.

LHBLutropin subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Promotes spermatogenesis and ovulation by stimulating the testes and ovaries to synthesize steroids

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (5)
G alpha (s) signalling eventsHormone ligand-binding receptorsGlycoprotein hormonesAndrogen biosynthesisMineralocorticoid biosynthesis
MECANISMO DE DOENÇA

Hypogonadotropic hypogonadism 23 with or without anosmia

A form of hypogonadotropic hypogonadism, a group of disorders characterized by absent or incomplete sexual maturation by the age of 18 years, in conjunction with low levels of circulating gonadotropins and testosterone and no other abnormalities of the hypothalamic-pituitary axis. HH23 male patients have normal sexual differentiation, reduced or absent Leydig cells, reduced or absent spermatogenesis, and absence of spontaneous puberty. Female patients exhibit normal pubertal development and menarche, followed by oligomenorrhea and anovulatory secondary amenorrhea.

EXPRESSÃO TECIDUAL(Tecido-específico)
Pituitária
3093.6 TPM
Testículo
8.6 TPM
Pâncreas
4.2 TPM
Estômago
2.3 TPM
Intestino delgado
1.3 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (1)
hypogonadotropic hypogonadism 23 with or without anosmia
HGNC:6584UniProt:P01229
LHCGRLutropin-choriogonadotropic hormone receptorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor for lutropin-choriogonadotropic hormone (PubMed:11847099). The activity of this receptor is mediated by G proteins which activate adenylate cyclase (PubMed:11847099)

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
G alpha (s) signalling eventsHormone ligand-binding receptors
MECANISMO DE DOENÇA

Familial male precocious puberty

In FMPP the receptor is constitutively activated.

EXPRESSÃO TECIDUAL(Tecido-específico)
Nervo tibial
5.2 TPM
Esôfago - Muscular
4.6 TPM
Ovário
1.9 TPM
Esôfago - Junção
1.7 TPM
Testículo
0.9 TPM
OUTRAS DOENÇAS (4)
familial male-limited precocious pubertyLeydig cell hypoplasia, type 1Leydig cell hypoplasia due to complete LH resistanceLeydig cell hypoplasia due to partial LH resistance
HGNC:6585UniProt:P22888

Variantes genéticas (ClinVar)

108 variantes patogênicas registradas no ClinVar.

🧬 LHCGR: NM_000233.4(LHCGR):c.384-2A>G ()
🧬 LHCGR: NM_000233.4(LHCGR):c.947+1G>C ()
🧬 LHCGR: NM_000233.4(LHCGR):c.1403_1404dup (p.Thr469fs) ()
🧬 LHCGR: NM_000233.4(LHCGR):c.398C>G (p.Thr133Arg) ()
🧬 LHCGR: NM_000233.4(LHCGR):c.1493C>T (p.Ala498Val) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 3 variantes classificadas pelo ClinVar.

3
Patogênica (100.0%)
VARIANTES MAIS SIGNIFICATIVAS
LHCGR: NM_000233.4(LHCGR):c.866+1515_948-2168del [Pathogenic]
LHCGR: NM_000233.4(LHCGR):c.1874T>A (p.Ile625Lys) [Pathogenic]
LHCGR: NM_000233.4(LHCGR):c.391T>C (p.Cys131Arg) [Pathogenic]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Hipoplasia das células de Leydig

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥇Melhor nível de evidência: Meta-análise
Timeline de publicações
26 papers (10 anos)
#1

NR2F2 regulation of interstitial cell fate in the embryonic mouse testis and its impact on differences of sex development.

Nature communications2025 Apr 29

Testicular fetal Leydig cells produce androgens essential for male reproductive development. Impaired fetal Leydig cell differentiation leads to differences of sex development including hypospadias, cryptorchidism, and infertility. Despite fetal Leydig cells are thought to originate from proliferating progenitor cells in the testis interstitium, the precise mechanisms governing the interstitial cells to fetal Leydig cell transition remain elusive. Using mouse models and single-nucleus multiomics, we find that fetal Leydig cells arise from a Nr2f2-positive interstitial population. Embryonic deletion of Nr2f2 in mouse testes results in differences of sex development, including dysgenic testes, Leydig cell hypoplasia, cryptorchidism, and hypospadias. By combining single-nucleus multiomics and NR2F2 ChIP-seq we find that NR2F2 promotes the progenitor fate while suppresses Leydig cell differentiation by modulating key transcription factors and downstream genes. Our findings establish Nr2f2 as a crucial regulator of fetal Leydig cell differentiation and provide molecular insights into differences of sex development linked to Nr2f2 mutations.

#2

[Type II Leydig cell hypoplasia caused by LHCGR gene mutation: a case report].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2025 Feb 15

The patient, assigned female at birth and aged 1 year and 7 months, presented with clinical manifestations of 46,XY disorders of sex development. The external genitalia exhibited a severely undermasculinized phenotype. Laboratory tests and gonadal biopsy indicated poor Leydig cell function and good Sertoli cell function. Genetic testing revealed compound heterozygous mutations of c.867-2A>C and c.547G>A (p.G183R) in the LHCGR gene. The patient was ultimately diagnosed with type II Leydig cell hypoplasia. Type II Leydig cell hypoplasia presents a broad spectrum of clinical phenotypes, characterized by a lack of parallel function between Leydig cells and Sertoli cells, and significant individual variability in spermatogenesis and gender assignment. This condition should be considered when there is poor Leydig cell function but good development of Wolffian duct derivatives. 患儿,社会性别女性,1岁7个月,临床表现为46,XY性发育异常,外生殖器呈重度男性化不全表型,实验室检查及性腺活检提示睾丸间质细胞功能差而支持细胞功能良好,基因检测发现LHCGR基因存在c.867-2A>C及c.547G>A(p.G183R)复合杂合变异,最终诊断为Ⅱ型间质细胞发育不全。Ⅱ型间质细胞发育不全临床表型谱广,睾丸间质细胞与支持细胞功能不平行,生精功能及性别选择个体化差异大,当睾丸间质细胞功能差而华氏管发育良好时需考虑该病。.

#3

Molecular pathogenesis, diagnosis, and management challenges in complete androgen insensitivity syndrome.

Frontiers in endocrinology2025

Complete androgen insensitivity syndrome (CAIS) is a rare X-linked recessive disorder of sex development (DSD) caused by androgen receptor (AR) gene mutation and present with female phenotypes with male chromosomal karyotype. Primitive bipotent gonads in CAIS differentiate into testes producing androgens and antimüllerian hormone (AMH). However, androgens cannot stimulate embryonic wolffian ducts into male internal reproductive organs owing to AR defect and hormone resistance, while AMH induces the regression of müllerian ducts with the absence of uterus, fallopian tubes, and upper third of the vagina. Thus, with male sex chromosome and testes, individuals with CAIS present with a typical female phenotype, primary amenorrhea (PA) and infertility, spontaneous thelarche during puberty, absent or sparse axillary/pubic hair, and increased risk of gonadal tumors in cryptorchidism. Though theoretically CAIS can be screened prenatally through a discrepancy between chromosomal karyotype and fetal external genitalia, suspected in bilateral inguinal "hernia" cases with female genital phenotype, and considered in cases with elevated testosterone (T) levels but no signs of virilization, the lack of typical symptoms brings great challenges to diagnosis and management. Endocrinological hormone assay is helpful for the identification of CAIS which reveals normal or elevated T levels, elevated luteinizing hormone for impairment of negative feedback of T, and normal follicle-stimulating hormone which is regulated by both sex hormones and inhibin. The diagnosis of CAIS after puberty is similar to the diagnostic workflow of PA with additional tests and should be differentiated with PA-related etiologies and other kinds of DSD, such as Swyer syndrome, Mayer-Rokitanskey-Küster-Haüser syndrome, Leydig cell hypoplasia, and several steroidogenic enzymatic deficiencies. Clinical manifestations, hormonal profiles, chromosomal karyotype, and pelvic imaging can provide comprehensive information for diagnosis. AR gene test or binding capacity can be performed for definitive diagnosis. The management of CAIS includes gonadectomy, hormone supplementation, and psychological support and education. Although with the development of molecular biology and awareness of the clinical entity more cases were reported, diagnostic and management challenges exist due to the disease-related and treatment-related stress including the rarity, untypical clinical manifestations, increased risk of gonadal malignancy, and its influence on physiology and psychology. This review provides a comprehensive overview of the molecular pathogenesis, pathophysiology, diagnostic evaluation, differential diagnosis, and management of CAIS.

#4

Histopathologic effects of mobile phone radiation exposure on the testes and sperm parameters: a systematic literature review of animal studies.

Frontiers in reproductive health2024

Male infertility, often attributed to insufficient production of healthy and active sperm, can be exacerbated by electromagnetic radiation emitted from mobile phones, which disrupts normal spermatogenesis and leads to a notable decline in sperm quality. The main targets of mobile phone-induced damage in the testes are Leydig cells, seminiferous tubules, and sperm cells. The aim of this systematic literature review is to identify histopathological changes in the testes due to mobile phone radiation exposure and to examine its effects on sperm parameters in experimental animals. In this systematic review, an extensive literature search was conducted across databases such as PubMed, ScienceDirect, Hinari, and Google scholar. A total of 752 studies were identified for screening, and 18 studies were deemed eligible for data extraction. Studies have identified histopathological alterations in testicular tissue caused by mobile phone radiation, such as reduced seminiferous tubule diameter, tunica albuginea and germinal epithelial thickness, Leydig cell hypoplasia, and increased intertubular space. Consistent exposure to mobile phone radiation has been shown to significantly reduce sperm count, motility, and viability, while also increasing abnormal sperm morphology in male rats, mice, and rabbits. Animal studies indicate that electromagnetic radiation from mobile phones can negatively impact testicular tissue and sperm parameters, including sperm count, motility, viability, and morphology. As a precaution, preventive measures are recommended to minimize potential risks from mobile phone exposure, and further research is needed to fully understand its effects on human reproductive health.

#5

NR2F2 regulation of interstitial to fetal Leydig cell differentiation in the testis: insights into differences of sex development.

bioRxiv : the preprint server for biology2024 Sep 16

Testicular fetal Leydig cells are a specialized cell type responsible for embryo masculinization. Fetal Leydig cells produce androgens, that induce the differentiation of male reproductive system and sexual characteristics. Deficiencies in Leydig cell differentiation leads to various disorders of sex development and male reproductive defects such as ambiguous genitalia, hypospadias, cryptorchidism, and infertility. Fetal Leydig cells are thought to originate from proliferating progenitor cells in the testis interstitium, marked by genes like Arx , Pdgfra , Tcf21 and Wnt5a . However, the precise mechanisms governing the transition from interstitial cells to fetal Leydig cells remain elusive. Through integrated approaches involving mouse models and single-nucleus multiomic analyses, we discovered that fetal Leydig cells originate from a Nr2f2 -positive non-steroidogenic interstitial cell population. Embryonic deletion of Nr2f2 in mouse testes resulted in disorders of sex development, including dysgenic testes, Leydig cell hypoplasia, cryptorchidism, and hypospadias. We found that NR2F2 promotes the progenitor cell fate while suppresses Leydig cell differentiation by directly and indirectly controlling a cohort of transcription factors and downstream genes. Bioinformatic analyses of single-nucleus ATAC-seq and NR2F2 ChIP-seq data revealed putative transcription factors co-regulating the process of interstitial to Leydig cell differentiation. Collectively, our findings not only highlight the critical role of Nr2f2 in orchestrating the transition from interstitial cells to fetal Leydig cells, but also provide molecular insight into the disorders of sex development as a result of Nr2f2 mutations.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC43 artigos no totalmostrando 30

2025

Molecular pathogenesis, diagnosis, and management challenges in complete androgen insensitivity syndrome.

Frontiers in endocrinology
2025

NR2F2 regulation of interstitial cell fate in the embryonic mouse testis and its impact on differences of sex development.

Nature communications
2025

[Type II Leydig cell hypoplasia caused by LHCGR gene mutation: a case report].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2024

Histopathologic effects of mobile phone radiation exposure on the testes and sperm parameters: a systematic literature review of animal studies.

Frontiers in reproductive health
2024

NR2F2 regulation of interstitial to fetal Leydig cell differentiation in the testis: insights into differences of sex development.

bioRxiv : the preprint server for biology
2024

LHCGR inactivating variants: single center experience and systematic review of phenotype-genotype of 46,XY and 46,XX patients.

Endocrine connections
2024

Expanding the phenotypic spectrum of LHCGR signal peptide insertion variant: novel clinical and allelic findings causing Leydig cell hypoplasia type II.

Hormones (Athens, Greece)
2022

Novel homozygous inactivating mutation in the luteinizing hormone receptor gene (LHCGR) associated with 46, XY DSD in a Moroccan family.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2022

Androgens and spermatogenesis.

Annales d'endocrinologie
2022

A rare cause of primary amenorrhea: LHCGR gene mutations.

European journal of obstetrics, gynecology, and reproductive biology
2022

46 XY undervirulized male DSD: Reporting a patient with prenatally diagnosed disorder/difference of sex development (DSD) with heterozygous LHCGR mutations.

Urology case reports
2020

[46,XY DSD induced by a novel mutation c.458T>C (p.Leu153Pro) of the LHCGR gene: A case report and review of the literature].

Zhonghua nan ke xue = National journal of andrology
2021

Primary Amenorrhea Due to Anatomical Abnormalities of the Reproductive Tract: Molecular Insight.

International journal of molecular sciences
2021

Leydig cell hypoplasia type 1 diagnosed in early childhood with inactivating mutation in LHCGR gene.

Oxford medical case reports
2020

[Genetic diagnosis for a patient with Leydig cell hypoplasia caused by two novel variants of LHCGR gene].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2020

Novel mutations of the LHCGR gene in two families with 46,XY DSD causing Leydig cell hypoplasia I.

Hormones (Athens, Greece)
2020

A novel variant in LCHGR gene in 3 siblings with type 1 Leydig cell hypoplasia.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
2020

LEYDIG CELL HYPOPLASIA: A UNIQUE PARADOX IN THE DIAGNOSIS OF 46,XY DISORDERS OF SEX DEVELOPMENT.

AACE clinical case reports
2019

Pregnancy and Live Birth In Women With Pathogenic LHCGR Variants Using Their Own Oocytes.

The Journal of clinical endocrinology and metabolism
2019

The importance of the multiplex ligation-dependent probe amplification in the identification of a novel two-exon deletion of the NR5A1 gene in a patient with 46,XY differences of sex development.

Molecular biology reports
2019

Diseases caused by mutations in luteinizing hormone/chorionic gonadotropin receptor.

Progress in molecular biology and translational science
2019

Novel Compound Heterozygous Variants in the LHCGR Gene in a Genetically Male Patient with Female External Genitalia.

Journal of clinical research in pediatric endocrinology
2018

Novel compound heterozygous variants in the LHCGR gene identified in a subject with Leydig cell hypoplasia type 1.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2017

Birth Weight in Different Etiologies of Disorders of Sex Development.

The Journal of clinical endocrinology and metabolism
2016

Testosterone and Varicocele.

The Urologic clinics of North America
2014

What lessons can be learned from testicular histology in undescended testes?

Translational andrology and urology
2016

Misfolding Ectodomain Mutations of the Lutropin Receptor Increase Efficacy of Hormone Stimulation.

Molecular endocrinology (Baltimore, Md.)
2015

A new variant in signal peptide of the human luteinizing hormone receptor (LHCGR) affects receptor biogenesis causing leydig cell hypoplasia.

Human molecular genetics
2015

Quality of Life and Psychological Adjustment of Women Living with 46,XY Differences of Sex Development.

The journal of sexual medicine
2015

A novel inactivating mutation of the LH/chorionic gonadotrophin receptor with impaired membrane trafficking leading to Leydig cell hypoplasia type 1.

European journal of endocrinology
Ver todos os 43 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Hipoplasia das células de Leydig.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Hipoplasia das células de Leydig

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. NR2F2 regulation of interstitial cell fate in the embryonic mouse testis and its impact on differences of sex development.
    Nature communications· 2025· PMID 40295478mais citado
  2. [Type II Leydig cell hypoplasia caused by LHCGR gene mutation: a case report].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics· 2025· PMID 39962787mais citado
  3. Molecular pathogenesis, diagnosis, and management challenges in complete androgen insensitivity syndrome.
    Frontiers in endocrinology· 2025· PMID 41163677mais citado
  4. Histopathologic effects of mobile phone radiation exposure on the testes and sperm parameters: a systematic literature review of animal studies.
    Frontiers in reproductive health· 2024· PMID 39896841mais citado
  5. NR2F2 regulation of interstitial to fetal Leydig cell differentiation in the testis: insights into differences of sex development.
    bioRxiv : the preprint server for biology· 2024· PMID 39345510mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:755(Orphanet)
  2. MONDO:0019155(MONDO)
  3. GARD:3244(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q6538005(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Hipoplasia das células de Leydig
Compêndio · Raras BR

Hipoplasia das células de Leydig

ORPHA:755 · MONDO:0019155
Prevalência
<1 / 1 000 000
Casos
70 casos conhecidos
CID-10
Q56.1 · Pseudo-hermafroditismo masculino, não classificado em outra parte
CID-11
Início
Neonatal
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0860158
EuropePMC
Wikidata
Papers 10a
Evidência
🥇 Meta-análise
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades